Comorbidities and costs in HIV patients: A retrospective claims database analysis in Germany

被引:20
作者
Christensen, Stefan [1 ,2 ]
Wolf, Eva [3 ]
Altevers, Julia [4 ]
Diaz-Cuervo, Helena [5 ]
机构
[1] Ctr Interdisciplinary Med CIM Infect Dis, Munster, Germany
[2] Muenster Univ Hosp, Dept Gastroenterol & Hepatol, Munster, Germany
[3] MUC Res, Munich, Germany
[4] Xcenda GmbH, Hannover, Germany
[5] Gilead Sci Europe, Greater London, England
来源
PLOS ONE | 2019年 / 14卷 / 11期
关键词
MYOCARDIAL-INFARCTION; RISK; TENOFOVIR; AGE; INFECTION;
D O I
10.1371/journal.pone.0224279
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
People living with human immunodeficiency virus (PLHIV) are at high risk of developing non-HIV related comorbidities, particularly at older ages. In a retrospective claims database analysis, we compared PLHIV to a matched, non-HIV cohort to assess the prevalence of comorbidities and healthcare costs in PLHIV and the general non-HIV population in Germany. In total, 2,132 adult patients with HIV were identified in the InGef research database with HIV ICD-10 diagnosis within each year from 2011 to 2014. Of these, 1,969 could be matched to a control cohort of 3,938 individuals (1:2 ratio). Matching criteria included age, gender and socio-economic variables. The prevalence of acute renal disease (0.5% vs. 0.2%, p = 0.045), bone fractures due to osteoporosis (6.4% vs. 2.1%, p<0.001), chronic renal disease (4.3% vs. 2.4%, p<0.001), cardiovascular disease (12.8% vs. 10.4%, p = 0.006), Hepatitis B (5.9% vs. 0.3%, p<0.001) and Hepatitis C infection (8.8% vs. 0.3%, p<0.001) was significantly higher in PLHIV compared to the matched non-HIV cohort. Mean costs excluding costs for antiretroviral therapy (ART) were significantly higher in the HIV cohort (8,049(sic) vs. 3,658(sic), p<0.05). On average, PLHIV incurred excess costs of 16,441(sic) for ART, 2,747(sic) for pharmaceuticals excluding ART (p<0.05), 1,441(sic) for outpatient care (p<0.05) and 321(sic) for inpatient care (p<0.05). Devices and remedies' costs were significantly higher in the control cohort with excess costs of 113(sic) (p<0.05). Considering mean total costs, excluding ART, excess costs for PLHIV amounted to 8,049(sic) (p<0.05). This analysis demonstrated an increased comorbidity and economic burden of PLHIV compared to matched controls. Our findings suggest that HIV remains an area of high unmet medical need. To improve patient outcomes, adequate HIV management including regular monitoring, screening for comorbidities and optimal ART selection throughout the life course of PLHIV are of key importance.
引用
收藏
页数:11
相关论文
共 26 条
  • [1] Comparison of Risk and Age at Diagnosis of Myocardial Infarction, End-Stage Renal Disease, and Non-AIDS-Defining Cancer in HIV-Infected Versus Uninfected Adults
    Althoff, Keri N.
    McGinnis, Kathleen A.
    Wyatt, Christina M.
    Freiberg, Matthew S.
    Gilbert, Cynthia
    Oursler, Krisann K.
    Rimland, David
    Rodriguez-Barradas, Maria C.
    Dubrow, Robert
    Park, Lesley S.
    Skanderson, Melissa
    Shiels, Meredith S.
    Gange, Stephen J.
    Gebo, Kelly A.
    Justice, Amy C.
    [J]. CLINICAL INFECTIOUS DISEASES, 2015, 60 (04) : 627 - 638
  • [2] Characteristics and external validity of the German Health Risk Institute (HRI) Database
    Andersohn, Frank
    Walker, Jochen
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 (01) : 106 - 109
  • [3] [Anonymous], WORLD DRUG REP 2014
  • [4] [Anonymous], IND KART RAUM STADT
  • [5] [Anonymous], 2014, VITAL HLTH STAT
  • [6] Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents
    Bedimo, Roger
    Maalouf, Naim M.
    Zhang, Song
    Drechsler, Henning
    Tebas, Pablo
    [J]. AIDS, 2012, 26 (07) : 825 - 831
  • [7] Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review
    Brown, Todd T.
    Qaqish, Roula B.
    [J]. AIDS, 2006, 20 (17) : 2165 - 2174
  • [8] Centers for Disease Control and Prevention, 2016, 16 CDCP, V16
  • [9] HIV Infection and the Risk of Acute Myocardial Infarction
    Freiberg, Matthew S.
    Chang, Chung-Chou H.
    Kuller, Lewis H.
    Skanderson, Melissa
    Lowy, Elliott
    Kraemer, Kevin L.
    Butt, Adeel A.
    Goetz, Matthew Bidwell
    Leaf, David
    Oursler, Kris Ann
    Rimland, David
    Barradas, Maria Rodriguez
    Brown, Sheldon
    Gibert, Cynthia
    McGinnis, Kathy
    Crothers, Kristina
    Sico, Jason
    Crane, Heidi
    Warner, Alberta
    Gottlieb, Stephen
    Gottdiener, John
    Tracy, Russell P.
    Budoff, Matthew
    Watson, Courtney
    Armah, Kaku A.
    Doebler, Donna
    Bryant, Kendall
    Justice, Amy C.
    [J]. JAMA INTERNAL MEDICINE, 2013, 173 (08) : 614 - 622
  • [10] Class of antiretroviral drugs and the risk of myocardial infarction
    Friis-Moller, Nina
    Reiss, Peter
    Sabin, Caroline A.
    Weber, Rainer
    Monforte, Antonella d'Arminio
    El-Sadr, Wafaa
    De Wit, Stephane
    Kirk, Ole
    Fontas, Eric
    Law, Matthew G.
    Phillips, Andrew
    Lundgren, Jens D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (17) : 1723 - 1735